Pfizer invests $500 million in expanding gene therapy facility

By Carl O'Donnell (Reuters) - Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.

Reuters August 22, 2019 00:06:00 IST
Pfizer invests $500 million in expanding gene therapy facility

Pfizer invests 500 million in expanding gene therapy facility

By Carl O'Donnell

(Reuters) - Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.

The investment will add additional capacity and capabilities to a facility that makes some of Pfizer's most closely watched experimental treatments.

The Sanford plant manufactures therapies used for the company's late-stage experimental treatments for Duchenne Muscular Dystrophy (DMD) and hemophilia B therapies, among other gene therapies.

It is also responsible for making components for some of Pfizer's vaccines, such as Prevenar 13, which had nearly $6 billion in sales in 2018.

“The expansion of the Sanford site is expected to create hundreds of highly skilled jobs, which would increase Sanford’s high-tech manufacturing environment and is part of our overall plan to invest approximately $5 billion in U.S.-based capital projects over the next several years,” Mike McDermott, president of Pfizer Global Supply, said in a statement announcing the investment.

Pfizer has been looking to move into innovative and fast- growing therapeutic areas such as oncology and gene therapy in recent years as it prepares for a looming patent cliff on some of its biggest drugs in the mid-2020's.

In March, Pfizer agreed to buy gene therapies under development at French biotech Vivet Therapeutics for as much as $636 million. It has gene therapies under development for diseases including DMD, hemophilia, and Amyotrophic lateral sclerosis (ALS).

Pfizer is in a race with rivals such as Sarepta Therapeutics Inc to be the first to bring a curative, late-stage treatment to DMD market.

Sarepta recently faced a setback when the U.S. Food and Drug Administration, citing safety risks, rejected its application to market a DMD treatment called Vyondys 53, which is not a gene therapy.

Pfizer has been making big moves toward becoming a more streamlined business focused exclusively on innovative drugs.

Late last year, it agreed to combine its consumer health business with that of GlaxoSmithKline Plc.

In July, it spun off its established pharmaceutical business, which contains its off-patent drugs, and combined it with generic drugmaker Mylan NV.

(Reporting by Carl O'Donnell; Editing by Dan Grebler)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

France, Germany to agree to NATO role against Islamic State - sources
| Reuters
World

France, Germany to agree to NATO role against Islamic State - sources | Reuters

By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States

China's Xi says navy should become world class
| Reuters
World

China's Xi says navy should become world class | Reuters

BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.